MorphoSys AG buy Biggybaer
Summary
This prediction is currently active. The BUY prediction by Biggybaer for MorphoSys AG has seen massive gains of 103.69%. This prediction currently runs until 11.12.24. The prediction end date can be changed by Biggybaer at any time. Biggybaer has 30% into this predictionMorphoSys is a German biopharmaceutical company that develops innovative therapies for the treatment of cancer, autoimmune diseases, and other serious illnesses. The company specializes in developing monoclonal antibodies, which are highly specific and targeted therapies that recognize and bind to specific cancer cells or disease-causing proteins in the body. MorphoSys has a diverse pipeline of products in various stages of development, including several drugs that have shown promising results in clinical trials. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of over $4 billion.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
MorphoSys AG | -1.476% | -1.476% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by Biggybaer for this prediction
In the thread Morphosys AG diskutieren